Renal cell carcinoma, part 3.
Journal
Nursing
ISSN: 1538-8689
Titre abrégé: Nursing
Pays: United States
ID NLM: 7600137
Informations de publication
Date de publication:
01 Sep 2021
01 Sep 2021
Historique:
entrez:
31
8
2021
pubmed:
1
9
2021
medline:
4
9
2021
Statut:
ppublish
Résumé
Renal cell carcinoma (RCC) accounts for most renal malignancies. This article, the last in a three-part series, presents treatment options for RCC using the American Joint Committee on Cancer Tumor, Node, and Metastasis staging system as a framework, as well as nursing-care options for patients undergoing partial or radical nephrectomy.
Identifiants
pubmed: 34463651
doi: 10.1097/01.NURSE.0000769804.33935.a1
pii: 00152193-202109000-00009
doi:
Types de publication
Journal Article
Langues
eng
Pagination
30-38Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Wasserman M, Sobel D, Pareek G. Choice of surgical options in kidney cancer and surgical complications. Semin Nephrol . 2020;40(1):42–48.
Kondo T. Treatment overview. In: Oya M, ed. Renal Cell Carcinoma: Molecular Features and Treatment Updates . Tokyo, Japan: Springer; 2017:177–207.
Santoni M, Cimadamore A, Cheng L, et al. Targeted treatment of renal cell carcinoma. In: Divatia MK, Ozcan A, Guo CC, Ro JY, eds. Kidney Cancer: Recent Advances in Surgical and Molecular Pathology . Cham, Switzerland: Springer; 2020:399–408.
Siddiqui SN, Haas CR, McKiernan JM. Epidemiology, screening, and clinical staging. In: Libertino JA, Gee JR, eds. Renal Cancer: Contemporary Management . 2nd ed. Cham, Switzerland: Springer; 2020:1–18.
Pullen RL Jr. Renal cell carcinoma, part 1. Nursing . 2021;51(7):34–40.
Pullen RL. Renal cell carcinoma, part 2. Nursing . 2021;51(8):24–29.
American Urological Association. Renal mass and localized renal cancer: AUA guideline. 2017. www.auanet.org/guidelines/renal-cancer-renal-mass-and-localized-renal-cancer-guideline .
Bamias A, Escudier B, Sternberg CN, et al. Current clinical practice guidelines for the treatment of renal cell carcinoma: a systematic review and critical evaluation. Oncologist . 2017;22(6):667–679.
Donin NM, Huang WC. Rationale for partial nephrectomy: current practice patterns. In: Libertino JA, Gee JR, eds. Renal Cancer: Contemporary Management . 2nd ed. Cham, Switzerland: Springer; 2020:59–184.
Unadkat P, Olum AF, Gershman B. The role of lymphadenectomy in patients with advanced renal cell carcinoma. Urol Clin North Am . 2020;47(3):371–377.
Libertino JA, Wotkowicz C, Gee JR. Surgery for renal cell carcinoma with thrombus extension into the vena cava. In: Libertino JA, Gee JR, eds. Renal Cancer: Contemporary Management . 2nd ed. Cham, Switzerland: Springer; 2020:259–280.
Deleuze A, Saout J, Dugay F, et al. Immunotherapy in renal cell carcinoma: the future is now. Int J Mol Sci . 2020;21(7):2532.
Ghali F, Patel SH, Derweesh IH. Current status of immunotherapy for localized and locally advanced renal cell carcinoma. J Oncol . 2019;2019:7309205.
Immunotherapy. In: Olsen MM, LeFebvre K, Brassil KJ, eds. Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice . Pittsburgh, PA: Oncology Nursing Society; 2019:149–189.
Chen EJ. Systemic therapies for the treatment of renal cell carcinoma. In: Libertino JA, Gee JR, eds. Renal Cancer: Contemporary Management . 2nd ed. Cham, Switzerland: Springer; 2020:401–410.
Biles MJ, Patel HD, Allaf ME. Cytoreductive nephrectomy in the era of tyrosine kinase and immuno-oncology checkpoint inhibitors. Urol Clin North Am . 2020;47(3):359–370.
Hall B, Abel EJ. The evolving role of metastasectomy for patients with metastatic renal cell carcinoma. Urol Clin North Am . 2020;47(3):379–388.
Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med . 2018;378(14):1277–1290.
Targeted and immunotherapy agents. In: Karp DD, Falchook GS, eds. Handbook of Targeted Cancer Therapy and Immunotherapy . 2nd ed. Philadelphia, PA: Wolters Kluwer; 2019:295–369.
Xie J, Wang X, Proud CG. mTOR inhibitors in cancer therapy. F1000 Research. 2016. https://f1000research.com/articles/5-2078 .
Targeted therapy. In: Olsen MM, LeFebvre K, Brassil KJ, eds. Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice . Pittsburgh, PA: Oncology Nursing Society; 2019:103–139.
National Comprehensive Cancer Network. NCCN guidelines for patients: kidney cancer. 2017. www.nccn.org/patients/guidelines/content/PDF/nccnquickguide-kidney-patient.pdf .
Miccio JA, Oladeru OT, Ma SJ, Johung KL. Radiation therapy for patients with advanced renal cell carcinoma. Urol Clin North Am . 2020:47(3):399–411.
Jhaveri KD, Wanchoo R, Sakhiya V, Ross DW, Fishbane S. Adverse renal effects of novel molecular oncologic targeted therapies: a narrative review. Kidney Int Rep . 2016;2(1):108–123.
Cutaneous toxicities. In: Olsen MM, LeFebvre K, Brassil KJ, eds. Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice . Pittsburgh, PA: Oncology Nursing Society; 2019:501–515.
American Cancer Society. Targeted therapy side effects: skin changes. 2020. www.cancer.org/treatment/treatments-and-side-effects/treatment-types/targeted-therapy/side-effects.html .
Barton-Burke M, Ciccolini K, Mekas M, Burke S. Dermatologic reactions to targeted therapy: a focus on epidermal growth factor receptor inhibitors and nursing care. Nurs Clin North Am . 2017;52(1):83–113.
National Institutes of Health, National Cancer Institute. Seer training modules. American Joint Committee on Cancer. https://training.seer.cancer.gov/staging/systems/ajcc .
American Cancer Society. Cancer staging. www.cancer.org/treatment/understanding-your-diagnosis/staging.html .
Gahart BL, Nazareno AR, Ortega MQ, eds. Gahart's 2021 Intravenous Medications: A Handbook for Nurses and Health Professionals . St. Louis, MO: Elsevier; 2021.
Vallerand AH, Sanoski CA, eds. Davis's Drug Guide for Nurses . 7th ed. Philadelphia, PA: F.A. Davis; 2021.